Video Experimental Relacionado
Updated: Jun 3, 2026
09:45
Motor and Hippocampal Dependent Spatial Learning and Reference Memory Assessment in a Transgenic Rat Model of Alzheimer's Disease with Stroke
Published on: March 22, 2016
La enfermedad de Alzheimer es la enfermedad de Alzheimer
Clive Ballard1, Serge Gauthier, Anne Corbett
1Wolfson Centre for Age-Related Diseases, King's College London, London, UK. clive.ballard@kcl.ac.uk
Lancet (London, England)
|March 5, 2011
Resumen
La enfermedad de Alzheimer afecta a millones de personas en todo el mundo, lo que requiere una mejor comprensión de sus causas, diagnóstico y factores de riesgo. Esta visión general destaca la evidencia reciente y discute posibles estrategias para la reducción del riesgo.
Área de la Ciencia:
- Neurología Neurología.
- Salud Pública La salud pública.
- Epidemiología La epidemiología.
Sus antecedentes:
- La enfermedad de Alzheimer (EA) es una de las principales causas de demencia, que afecta a un estimado de 24 millones de personas en todo el mundo.
- La AD plantea un desafío significativo para la salud pública, lo que subraya su estatus como una prioridad de investigación.
- Los tratamientos actuales manejan los síntomas de la EA, pero las terapias modificadoras de la enfermedad requieren una comprensión más profunda de la patogénesis.
Objetivo del estudio:
- Proporcionar una visión general de la evidencia reciente sobre la enfermedad de Alzheimer (EA).
- Para discutir la epidemiología, la patogénesis, el diagnóstico y el tratamiento de la enfermedad de Alzheimer.
- Explorar estrategias potenciales de reducción de riesgos para la enfermedad de Alzheimer y el deterioro cognitivo.
Principales métodos:
- Revisión de la literatura de las pruebas recientes.
- Síntesis de la comprensión actual de la patogénesis de la EA.
- Análisis de los avances en el diagnóstico, incluyendo biomarcadores y neuroimagen.
- Examen de los factores de riesgo y protectores identificados para la EA y la demencia.
Principales resultados:
- Avances significativos en la comprensión del riesgo de EA y los factores de protección.
- El desarrollo continuo de métodos de diagnóstico, con la necesidad de un consenso de biomarcadores.
- La evidencia sugiere el potencial de las intervenciones para reducir el riesgo de EA.
- Los tratamientos autorizados ofrecen alivio sintomático pero no modificación de la enfermedad.
Conclusiones:
- La investigación adicional es crucial para desarrollar tratamientos modificadores de la enfermedad para la enfermedad de Alzheimer.
- Se necesitan herramientas de diagnóstico mejoradas, incluidos paneles de biomarcadores validados.
- Comprender y mitigar los factores de riesgo es clave para reducir la carga de la enfermedad de Alzheimer y la demencia.
Videos de Conceptos Relacionados
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:30Dementia
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.
The progression of dementia is generally gradual.
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...